An Open-label, International, Multicenter, Dose Escalating, Phase I/II Study of HuMax-CD20 in Patients With Relapsed or Refractory Follicular Lymphoma Grade I-II

Trial Profile

An Open-label, International, Multicenter, Dose Escalating, Phase I/II Study of HuMax-CD20 in Patients With Relapsed or Refractory Follicular Lymphoma Grade I-II

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 23 Apr 2015

At a glance

  • Drugs Ofatumumab (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Sponsors Genmab; GlaxoSmithKline
  • Most Recent Events

    • 20 Apr 2015 Status changed from completed to withdrawn prior to enrolment as per ClinicalTrials.gov record.
    • 26 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top